Id: acc1861
Group: 2sens
Protein: HER3
Gene Symbol: ERBB3
Protein Id: P21860
Protein Name: ERBB3_HUMAN
PTM: methylation
Site: Tyr1307
Site Sequence: PGHQAPHVHYARLKTLRSLEA
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype:
Disease Cellline: MDA-MB-231
Disease Info:
Drug: neuregulin
Drug Info: -
Effect: modulate
Effect Info: "ROR1 phosphorylates the Tyr1307 site of HER3 under the stimulation of neuregulin. Subsequently, it recruits the LLGL2 - MAYA - NSUN6 complex to methylate Hippo/MST1, resulting in the inactivation of MST1 and the activation of YAP target genes, and inducing osteoclast differentiation and bone metastasis."
Note:
Score: 4.0
Pubmed(PMID): 28114269
Sentence Index:
Sentence:

Sequence & Structure:

MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid carcinoma DailyMed
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid neoplasm EMA
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 Active, not recruiting thyroid cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 4 - medullary thyroid gland carcinoma DailyMed
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ERBB3 PATRITUMAB Receptor tyrosine-protein kinase erbB-3 inhibitor 3 Terminated non-small cell lung carcinoma ClinicalTrials
ERBB3 POZIOTINIB Epidermal growth factor receptor inhibitor 3 Suspended non-small cell lung carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Active, not recruiting thyroid cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed thyroid cancer ClinicalTrials
ERBB3 PATRITUMAB Receptor tyrosine-protein kinase erbB-3 inhibitor 3 Terminated lung cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed lung cancer ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Active, not recruiting medullary thyroid gland carcinoma ClinicalTrials
ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 3 Withdrawn medullary thyroid gland carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Completed hepatocellular carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Completed head and neck squamous cell carcinoma ClinicalTrials
ERBB3 TARLOXOTINIB Epidermal growth factor receptor inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
ERBB3 CDX-3379 Receptor tyrosine-protein kinase erbB-3 inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Unknown status acute myeloid leukemia ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Terminated clear cell renal carcinoma ClinicalTrials
ERBB3 SAPITINIB Receptor tyrosine-protein kinase erbB-3 inhibitor 2 Completed colorectal adenocarcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Completed glioblastoma multiforme ClinicalTrials
ERBB3 POZIOTINIB Epidermal growth factor receptor inhibitor 2 Terminated lung adenocarcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Terminated follicular thyroid carcinoma ClinicalTrials
ERBB3 VANDETANIB Epidermal growth factor receptor inhibitor 2 Terminated mesothelioma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 1289 D Head and neck squamous cell carcinoma Phosphorylation 21281788
- - P Breast cancer/tumor/carcinoma Phosphorylation 11389077
- - P Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 21246584
Y 1289 U Ovarian cancer Phosphorylation 20227043
- - U Ovarian cancer/carcinoma Phosphorylation 22841590

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: